Loading organizations...
Generate Biomedicines develops protein therapeutics using its proprietary Generative Biology platform. This system integrates machine learning, biological engineering, and science to design novel proteins with precise therapeutic functions. The company programs new medicines directly, moving beyond traditional drug discovery by engineering custom biotherapeutics from biological principles identified in vast datasets.
Co-founded in 2018 by Flagship Pioneering scientists Avak Kahvejian, Geoffrey von Maltzahn, Molly Gibson, and Gevorg Grigoryan, the company emerged from foundational research at Flagship Labs. Their insight involved a machine learning-powered platform to deliberately generate novel biomedicines, aiming to revolutionize drug development by surpassing trial-and-error limitations.
Generate Biomedicines' products treat and cure diverse human diseases with novel protein therapeutics. Its vision is to transform biotherapeutic discovery and development, accelerating effective medicines for humanity’s most challenging illnesses. The platform increases therapeutic identification speed and success through continuous generation, measurement, and learning.
Generate Biomedicines has raised $640.0M across 2 funding rounds.
Generate Biomedicines has raised $640.0M in total across 2 funding rounds.
Generate Biomedicines has raised $640.0M in total across 2 funding rounds.
Generate Biomedicines's investors include Alchemy Ventures, Alumni Ventures, Craft Ventures, Flagship Pioneering, Gigascale Capital, iGlobe Partners, Menlo Ventures, Morgan Creek Capital Management, Multicoin Capital, Oak HC/FT, Pareto Holdings, Picus Capital.
Generate:Biomedicines is a biotechnology company pioneering Generative Biology™, an AI-driven platform that uses machine learning to design and optimize novel proteins for therapeutics, targeting immunology, oncology, and infectious diseases.[1][2][3] The company builds protein-based medicines like antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs), serving patients with intractable diseases by solving the inefficiencies of traditional trial-and-error drug discovery through de novo protein generation and rapid optimization for affinity, immunogenicity, and manufacturability.[1][6] It has demonstrated growth momentum with a $273 million Series C in 2023—the largest biotech Series C that year—over 42,000 proteins generated and tested, first-in-human trials for GB-0669 (SARS-CoV-2 antibody), and partnerships with Amgen and Novartis across multiple programs.[1][3][8]
Headquartered in Cambridge, Massachusetts, with 140k+ square feet in facilities, Generate operates at the intersection of machine learning, biological engineering, and medicine, backed by Flagship Pioneering.[1][2][3]
Generate:Biomedicines was founded in 2018 by Molly Gibson (computational and systems biology expert) and Gevorg Grigoryan (Chief Technology Officer), with support from Flagship Pioneering, to apply data-driven machine learning for decoding protein sequence-function relationships and creating novel therapeutics.[1][2][5] The idea emerged from replacing inefficient trial-and-error methods with generative models trained on millions of proteins, exemplified by their rapid 2020 response generating SARS-CoV-2 antibodies.[1][5]
Early traction included proving the platform's ability to generate antibodies and peptides against a dozen targets, outperforming traditional methods.[5] In 2021, Mike Nally (ex-Merck) became CEO, scaling infrastructure and collaborations; by 2023, funding fueled clinical trials and a 17-program pipeline.[1]
Generate rides the AI-in-biotech wave, merging machine learning with biological engineering to program biology like software, addressing R&D productivity crises where traditional discovery fails 90%+ of targets.[2][3][6][9] Timing aligns with explosive growth in generative AI (post-ChatGPT) applied to proteins, plus post-pandemic demand for fast antivirals and personalized meds amid rising chronic diseases.[1][5]
Market forces favor it: biotech funding rebound, AI hardware advances enabling massive protein datasets, and pharma's shift to partnerships for tech platforms.[1][8] Generate influences the ecosystem by democratizing biotherapeutics—licensing tech to partners, expanding pipelines, and proving AI can slash discovery timelines from years to months, inspiring competitors like Absci or Isomorphic Labs.[3][5][8]
Generate:Biomedicines is poised to lead AI-native drug discovery, with clinical readouts from GB-0669 and GB-0895 trials driving milestones, pipeline expansion (17+ programs), and deeper Amgen/Novartis deals.[1][6][8] Trends like multimodal AI, single-cell data integration, and regulatory nods for AI-designed drugs (e.g., FDA pilots) will accelerate its platform, potentially yielding first approvals by 2027-2028.
Its influence may evolve from pioneer to standard-setter, powering an era of "programmable medicines" that cure intractable diseases, fundamentally reshaping biotech from empirical to engineered—echoing its mission to expand biology's possibilities.[2][3]
Generate Biomedicines has raised $640.0M across 2 funding rounds. Most recently, it raised $270.0M Series C in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $270.0M Series C | Alchemy Ventures, Alumni Ventures, Craft Ventures, Flagship Pioneering, Gigascale Capital, iGlobe Partners, Menlo Ventures, Morgan Creek Capital Management, Multicoin Capital, Oak HC/FT, Pareto Holdings, Picus Capital, Ripio Ventures, Stellar Capital, Upload Ventures, Tony Xu, Abu Dhabi Investment Authority, Amgen Ventures, ARCH Venture Partners, Fidelity Management & Research Company, MAPS Capital, March Capital, NVentures, Pictet Alternative Advisors, T. Rowe Price Associates | |
| Nov 1, 2021 | $370.0M Series B | Alumni Ventures, Flagship Pioneering, Alaska Permanent Fund, Altitude Life Science Ventures, ARCH Venture Partners, T. Rowe Price Associates |